H&T Presspart is pleased to announce the opening of the new Plasma MDI can manufacturing facility at the Blackburn site in the UK.

The multi-million pound investment saw the creation of a purpose built cleanroom for the plasma manufacturing facility, incorporating a fully completely automated manufacturing process. This includes jig-filling, robotic jig loading, and new plasma manufacturing stations.

Tony Cross, Managing Director at H&T Presspart Blackburn, commented ‘This major investment will allow us to meet increasing market needs for our Plasma MDI cans. The technology helps support our customers improve patients’ lives, whilst maintaining our position in global markets. I would like to thank everyone involved in the project.’

H&T Presspart’s patent protected plasma process, manufactured under license from Portal Medical Ltd, treats the internal surfaces of our MDI canister to ensure there is reduced drug adhesion to the internal canister wall from the active pharmaceutical ingredients (API)

This solves a problem present in many other MDI cans and ensures the patient gets the correct dosage from their inhaler when delivering challenging single and multi-molecule formulations.

Another advantage of the plasma process is that it enhances drug stability in formulations where interactions with the aluminium substrate can lead to product degradation and reduced shelf life.

Plasma is a future-proofed technology and uses only standard high-purity industrial gases. In terms of sustainability, the technology is also environmentally friendly and produces no harmful waste products compared to other coating technologies.

Visit the plasma technology page on H&T Presspart’s website for more information.